Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy

Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy

The circulating tumor DNA (ctDNA), as a promising biomarker of liquid biopsy, has potential clinical relevance on the molecular diagnosis and monitoring of cancer. However, the trace concentration level of ctDNA in the peripheral blood restricts its extensive clinical application. Recently, high-thr...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 11; p. 692322
Main Authors: Li, Ming, Xie, Sisi, Lu, Chenyu, Zhu, Lingyun, Zhu, Lvyun
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 21-07-2021
Subjects:
cancer diagnosis
ctDNA detection
data science
liquid biopsy
Oncology
technological advancement
cancer diagnosis
technological advancement
data science
ctDNA detection
liquid biopsy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The circulating tumor DNA (ctDNA), as a promising biomarker of liquid biopsy, has potential clinical relevance on the molecular diagnosis and monitoring of cancer. However, the trace concentration level of ctDNA in the peripheral blood restricts its extensive clinical application. Recently, high-throughput-based methodologies have been leveraged to improve the sensitivity and specificity of ctDNA detection, showing a promising avenue towards liquid biopsy. This review briefly summarizes the high-throughput data features concerned by current ctDNA detection strategies and the technical obstacles, potential solutions, and clinical relevance of current ctDNA profiling technologies. We also highlight future directions improving the limit of detection of ctDNA for better clinical application. This review may serve as a reference for the crosslinks between data science and ctDNA-based liquid biopsy, benefiting clinical translation in advanced cancer diagnosis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Svetlana Tamkovich, Novosibirsk State University, Russia; Elizabeth A. Proctor, The Pennsylvania State University, United States
Edited by: George Calin, University of Texas MD Anderson Cancer Center, United States
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.692322